Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 410 Next >>

Filter Applied: treatment of neurologic disorder (Click to remove)

Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018

A young woman with symmetric weakness and behavioral disturbance
Neurol 90:e1442-e1447, Rosenberg, J.,et al, 2018

Atypical Parkinsonian Syndromes: A General Neurologists Perspective
Eur J Neurol 25:41-58, Deutschlander, A.B.,et al, 2018

Human Neurexin-3a Antibodies Associate with Encephalitis and Alter Synapse Development
Neurol 86:2235-2242,2222, Gresa-Arribas, N.,et al, 2016

Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011

The Spectrum of Presentations of Venous Infarction Caused by Deep Cerebral Vein Thrombosis
Neurol 65:192-196, van den Bergh,W.M.,et al, 2005

Cerebral Venous Thrombosis
Neurol Clin 10:87-111, Ameri,A.&Bousser,M-G., 1992

Rocky Mountain Spotted Fever Encephalitis and "Starry Sky" Pattern on MRI, A Case Report
Neurologist 30:34-38, Mikhaiel,J.P.,et al, 2025

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025

Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025

Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025

A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025

A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025

Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025

Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025

New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025

Neuroimaging Findings in Children and Young Adults with Neurotoxicity after CAR T-Cell Therapy for B-Cell Malignancies
Neurol 105:e214086, McGuire,J.L.,et al, 2025

Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024

Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024

Clinicopathologic Conference, Reversible Cerebral Vasoconstriction Syndrome with Takotsubo Cardiomyopathy
NEJM 390:2108-2118, Case 18-2024, 2024

Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024

Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024

Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024

Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024

Clinicopathologic Conference, Cryptococcal Meningoencephalitis
NEJM 391:2361-2369, Case 40-2024, 2024

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

Neonatal Seizures
NEJM 388:1692-1700, Ropper.A.H., 2023

Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023

Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023

Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023

Mortality and Causes of Death in Children with Cerebral Palsy with Scoliosis Treated with and without Surgery
Neurol 101:e1787-e1792, Ahonen,M.,et al, 2023

Clinicopathologic Conference,Acquired Thrombotic Thrombocytopenic Purpura
NEJM 389:1804-1811, Case 34-2023, 2023

Clinicopathologic Conference, Anti-IgLON5 IgG-Associated Neurologic Disorder
NEJM 386:173-180, Case 1-2022, 2022

Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022

Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022

Clinicopathologic Conference, Encephalitis due to Behcets Disease
NEJM 387:925-933, Case 27-2022, 2022

Spontaneous Subarachnoid Haemorrhage
Lancet 400:846-862, Claassen, J. & Park, S., 2022

Rapidly Progressive Thalamic Dementia
Neurol 96:e809-e813, Rizzo, A.C.,et al, 2021

Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021

Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021

Safety and Efficacy of Coma Induction Following First-Line Treatment in Status Epilepticus
Neurol 97:e564-e576, DeStefano, P.,et al, 2021

Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021

Spontaneous Intracranial Hypotension
NEJM 385:2173-2178, Schievink, W.I., 2021

Relapse of Severe Neurosarcoidosis with Switch from Originator Infliximab to Biosimilar
Neurol 94:991-993, Kidd, D.P.,et al, 2020

Second Drug Okayed for Rare Central Nervous System Disease
JAMA 324:224, Jaklevic, M.C., 2020

One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020

Steroid-Responsive Encephalitis in Coronavirus Disease 2019
Ann Neurol 88:423-427, Pilotto, A.,et al, 2020

Migraine
NEJM 383:1866-1876, Ashina, M., 2020



Showing articles 0 to 50 of 410 Next >>